MABT5102A

DRUG3 trials

Sponsors

Genentech, Inc.

Conditions

Alzheimer's DiseaseHealthy Volunteer

Phase 1

A Study of the Safety, Tolerability, Pharmacokinetics, and Bioavailability of IV and SC MABT5102A in Healthy Volunteers

CompletedNCT00997919

Genentech, Inc.Healthy Volunteer

Start: 2009-10-31End: 2010-02-28Updated: 2017-05-30

Phase 2

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

CompletedNCT01343966

Genentech, Inc.Alzheimer's Disease

Start: 2011-04-30End: 2014-02-28Updated: 2017-07-12

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

CompletedNCT01397578

Genentech, Inc.Alzheimer's Disease

Start: 2011-08-31End: 2014-04-30Updated: 2017-07-12

Related Papers

Longitudinal Exposure-Response Modeling of Multiple Indicators of Alzheimer's Disease Progression.

2023-01-012 citations

Evaluating Digital Twins for Alzheimer’s Disease using Data from a Completed Phase 2 Clinical Trial

Alzheimer s & Dementia2022-12-019 citations

Evaluation of the Elecsys NeuroToolKit panel in early Alzheimer's disease populations across six clinical trials

Alzheimer s & Dementia2021-12-012 citations

Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Escalating Doses for up to 133 Weeks

Journal of Alzheimer s Disease2020-06-1764 citations

Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease

Alzheimer s Research & Therapy2020-01-2243 citations

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).

2018-09-19111 citations

[P4–013]: ESTIMATING CLINICALLY RELEVANT CHANGE AND DIFFERENCE THRESHOLDS FOR THE CLINICAL DEMENTIA RATING: SUM OF BOXES (CDR‐SB) FOR EARLY ALZHEIMER's DISEASE

Alzheimer s & Dementia2017-07-011 citations

P2‐006: Exploratory Analyses of Cognitive Effects of Crenezumab in a Mild Alzheimer's Disease Subpopulation of a Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Phase 2 Study (ABBY)

Alzheimer s & Dementia2016-07-014 citations